Getting Ready for Resistance to First-Gen NTRK Inhibitors

Just a few months ago, larotrectinib was approved for treating any NTRK+ tumor. Already, there are studies in place to address any mutations that emerge with the first-generation TRK-targeted agent.
Medscape Medical News